India, July 7 -- Tvardi Therapeutics (TVRD) announced Phase 1 results for TTI-109, its next-generation STAT3 inhibitor. The study confirmed rapid prodrug conversion, dose-proportional pharmacokinetics with exposures above the STAT3 IC50 and, in an exploratory pharmacodynamic analysis, reductions of up to 60% in STAT3-driven immune cell populations across Th17, Tfh and B cell subsets.
The company plans to advance TTI-109 into STAT3-driven dermatologic and gastrointestinal diseases. Tvardi noted that its ability to initiate these programs is subject to clearance of an Investigational New Drug application and the availability of additional funding.
In pre-market trading on NasdaqCM, Tvardi shares are up 3.48 percent to $2.08.
For More Such ...